TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01670279
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02318368
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00110435
Drug: MK0653A, ezetimibe (+) simvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00110435
Drug: Duration of Treatment: 4 wk placebo run in then 6 wk active
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01667497
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01864148
Drug: BIIB033
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00442494
Drug: intravenous hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT02078024
Drug: IVM plus ALB
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01232920
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: All methotrexate doses will be taken orally once per week in a divided dose (half in the morning, half in the evening), and should be taken with food. For the first two weeks, a loading dose of 15 mg/week orally will be administered to assess tolerability. After two weeks, the dose will be ramped up to 25 mg/week until the end of follow-up or until treatment failure due to intolerability, adverse events, or of lack of efficacy. If the study ophthalmologist decides to reduce the study treatment dose due to intolerability, the dose will be reduced to 20 mg per week while maintaining masking. If side effects persist and the study ophthalmologist wishes to reduce the dose a second time, the dose will be reduced to 15 mg per week.
Study: NCT02066792
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugar pill
Study: NCT01170494
Drug: ergocal1000 IU & cholecal 1000 IU orally daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: ergocalciferol 1000 IU and cholecalciferol 1000 IU orally every day
Study: NCT01170494
Drug: placebo orally everyday
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo orally everyday
Study: NCT02443142
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen 800 mg orally three times per day for two days for study subjects who are randomized to the ibuprofen arm.
Study: NCT02443142
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen 1000 mg orrally three times per day for two days for subjects who are randomized to the acetaminophen arm.
Study: NCT03002012
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: matched placebo tablet
Study: NCT03326492
Drug: Antivenom serum Inoserp Pan-Africa® injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participation to the study does not change usual follow-up of patients. All medical procedures will be performed and products will be used in a routine manner. Antivenom serum Inoserp Pan-Africa® injection will be decided according to the clinical evaluation of the patient.
Study: NCT01301287
Drug: Chlorella
Normalized name: Chlorella
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02182362
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00356772
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00885066
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00177970
Drug: intravenous immunoglobulin G (IVIG)
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVIG to be given IV to patients with C-Diff .
Study: NCT00177970
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to be given IV to patients with C-Diff
Study: NCT01928862
Drug: Prepopik® ½ Sachet x 2 (9-12 years)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01928862
Drug: Prepopik® 1 Sachet x 2 (9-12 years)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01928862
Drug: Prepopik® 1 Sachet x 2 (13-16 years)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03272477
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 12 weeks (4cycles) of 600 mg/sqm i.v. on day 1+8 or 12 weeks (4cycles) of 500 mg/sqm i.v. on day 1 in adjuvant therapy phase
Study: NCT01360658
Drug: Intravenous immunoglobulins
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single administration of 2 g/kg intravenous immunoglobulins over 2 days
Study: NCT00983268
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1000 mg taken by mouth on the days of radiation only.
Study: NCT02882555
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: A compressed air-driven nebuliser is controlled by a dosimeter and a valve is used to deliver similar inspiratory flows for 400 msec in children and 1200 msec in adults.
Study: NCT02581696
Drug: Lafutidine
Normalized name: lafutidine
DrugBank: Lafutidine (DB12770)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lafutidine 10mg, 1 tablet, bid
Study: NCT01463371
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 250 mg three times a week during three months
Study: NCT00634088
Drug: Ixabepilone + Lapatinib + Capecitabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Planned escalating doses of the triplet combination of ixabepilone, lapatinib, and capecitabine. No participants were enrolled in this arm due to premature termination of the study.
Study: NCT02290821
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02290821
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00647127
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl: 25microg/h
Study: NCT00647127
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo: '5microg/h' (not active drug, it is just called '5microg/h')
Study: NCT02592746
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine 1,250mg/m2 bid orally form day1 to day 14 q 3weeks
Study: NCT02244307
Drug: alpha-adrenergic blocker
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03626012
Drug: BIIB078
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as specified in the treatment arm.
Study: NCT03626012
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as specified in the treatment arm.
Study: NCT02483858
Drug: PQR 309
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention of this drug may include safety, tolerability, PK (pharmacokinetics) and efficacy
Study: NCT03248167
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: This project aims to determine whether cannabidiol (CBD) is effective in treating alcohol use disorder (AUD) comorbid posttraumatic stress disorder (PTSD). To address this aim, investigators will conduct a clinical trial in which CBD will be administered to 48 individuals with AUD comorbid with PTSD, and assess alcohol intake and PTSD symptoms. The aim is to test the hypothesis that CBD will reduce alcohol drinking in individuals with AUD comorbid with PTSD. To test this hypothesis, 48 otherwise healthy adult participants with moderate or severe AUD and PTSD will be randomized to treatment with either CBD (600 mg daily) or placebo, for a period of 6 weeks, such that both participants and study staff are blind to treatment condition.
Study: NCT01970241
Drug: NPH
Normalized name: ZENPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: NPH given per study table based on steroid dose and patient weight in kg.
Study: NCT01970241
Drug: Correction Factor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given at 2 units per 50 mg/dl over 200 mg/dl and increased to 3 units/50 mg/dl over 200 if glucose rises to over 300 mg/dl. Administered qid during study duration.
Study: NCT02388464
Drug: MTP-131
Approvals — FDA: no, EMA: no, PMDA: no
Description: MTP-131 (low dose) administered as single intravenous infusion over 4 hours
Study: NCT02388464
Drug: MTP-131
Approvals — FDA: no, EMA: no, PMDA: no
Description: MTP-131 (intermediate dose) administered as single intravenous infusion over 4 hours
Study: NCT02388464
Drug: MTP-131
Approvals — FDA: no, EMA: no, PMDA: no
Description: MTP-131 (high dose) administered as single intravenous infusion over 4 hours
Study: NCT02388464
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Comparator (at each dose cohort) administered as single intravenous infusion over 4 hours
Study: NCT00615693
Drug: AEB071
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02595866
Drug: Antiretroviral Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT00319202
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administration for 6 months
Study: NCT00310336
Drug: S-adenosyl-L-methionine
Normalized name: S-Adenosyl-L-Methionine (Sam-E)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01331746
Drug: APD515
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg oromucosal-oral administration qds for 7 days
Study: NCT01331746
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: qds for 7 days
Study: NCT03835481
Drug: Placebo to match BI 730357
Approvals — FDA: no, EMA: no, PMDA: no
Description: Film-coated tablet
Study: NCT03640507
Drug: Sterile saline
Normalized name: Aqua Care Sterile Saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention is a 30-second vaginal preparation or topical wash with three sterile saline-soaked sponge sticks.
Study: NCT00191945
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00392587
Drug: GW856553
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04416334
Drug: Symptomatic treatment (paracetamol or best symptomatic treatment based on doctor recommendations)
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Symptomatic treatment (paracetamol or best symptomatic treatment based on doctor recommendations).
Study: NCT01608737
Drug: PegIFN/RBV
Approvals — FDA: no, EMA: no, PMDA: no
Description: PegIFN/RBV for 48 weeks
Study: NCT00829881
Drug: Placebo Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single placebo capsule
Study: NCT01018017
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: For placebo product, the SRT2104 drug substance will be replaced by microcrystalline cellulose (Avicel® PH 105) to match the SRT2104 investigational product.
Study: NCT01018017
Drug: SRT2104
Approvals — FDA: no, EMA: no, PMDA: no
Description: SRT2104 will be supplied as hard gelatin capsules, with each containing 250mg SRT2104.
Study: NCT01014936
Drug: MSC2156119J
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00481195
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients were randomly assigned to begin oral treatment with placebo, which was titrated to 3 tablets. Placebo tablets matching the 50 mg armodafinil tablet were used in a manner identical to that of the armodafinil tablets. Study drug was titrated up to the target dosage of 3 tablets / day (daily dose was administered each morning). Patients began taking blinded study drug at a dose of 1 tablet daily on the day following the baseline visit. Doses were increased by 1 tablet to a dose of 2 tablets/day on Day 2 and 3, and then again by 1 tablet /day on day 4 for a target dose of 3 tablets/day. Following titration, patients continued taking 3 tablets/day of study drug for the duration of the study. If a patient was unable to tolerate (recurrent or persistent adverse events) the study drug, 1 reduction in dosage (ie, minimum dosage 2 tablets/day) was allowed. The dosage could not be increased after it was decreased.
Study: NCT03344042
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 100mcg Fentanyl
Study: NCT03344042
Drug: Sufentanil
Normalized name: Sufentanil
DrugBank: Sufentanil (DB00708)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10mcg sufentanil
Study: NCT02876900
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The study will evaluate placebo transdermal patch.
Study: NCT03999411
Drug: Nicoderm C-Q Transdermal Product
Normalized name: Nicoderm C-Q Transdermal Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 weeks of GlaxoSmithKline Nicoderm CQ (NRT)
Study: NCT03850873
Drug: TQB3616
Approvals — FDA: no, EMA: no, PMDA: no
Description: TQB3616 administerde days 28 of a 28-day schedule,doses ranging from 20m，40mg，60mg，80mg，100mg，120mg once daily
Study: NCT00909779
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo inhalation solution, twice daily (BID) for a duration of one year.
Study: NCT03710655
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal injection of 0.01 microliters
Study: NCT00649896
Drug: Mylan Estradiol Transdermal System 0.025 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00649896
Drug: Climara® Transdermal System 0.025 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01743287
Drug: Imotun capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imotun capsule: Avocado-Soya Unsaponifiables 300.03mg/Cap, per oral, a capsule once a day during for 24 weeks
Study: NCT01743287
Drug: Imotun capsule placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imotun capsule placebo: per oral, a capsule a day during 24 weeks
Study: NCT02738333
Drug: LDV/SOF
Approvals — FDA: no, EMA: no, PMDA: no
Description: 90/400 mg FDC tablet administered orally once daily
Study: NCT02738333
Drug: SOF
Normalized name: Kasof
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg tablet administered orally once daily
Study: NCT02009631
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04174287
Drug: F-18-AV45
Approvals — FDA: no, EMA: no, PMDA: no
Description: The study will enroll 200 patients with prodromal AD and mild AD dementia and 100 normal controls, men and women aged 55-80 years across core clinical criteria of prodromal AD and mild AD dementia based on IWG-2 criteria.
Study: NCT01098188
Drug: LFB-R603
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous administration, dose-escalation study
Study: NCT02971202
Drug: Hyperinsulinemic, euglycemic clamp
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will undergo an 8-hour hyperinsulinemic, euglycemic clamp to quantify insulin sensitivity at whole-body and tissue-specific levels. The following hormones will be infused in the study:~* insulin (12 mU/m\^2/min \[3x basal\] for 150 minutes, then 40 mU/m\^2/min \[10x basal\] for 180 minutes)~* glucagon (0.65 ng/kg/min \[1x basal\] for 330 minutes)~* somatostatin (60 ng/kg/min) These infusions will maintain a basal glucagon level and an increased insulin level in the blood that will be equal between all 3 cohorts.
Study: NCT02971202
Drug: 20% dextrose
Normalized name: Aminosyn II 4.25% in 20% Dextrose
Approvals — FDA: no, EMA: no, PMDA: no
Description: A variable infusion of 20% dextrose will be used to maintain plasma glucose within the euglycemic range throughout the hyperinsulinemic portion of the clamp. 6,6-H2 glucose will be infused at a low rate (0.033-0.22 µmol/kg/min) to determine glucose flux during the study.
Study: NCT01631487
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple (once daily for 21 days) oral doses of matching placebo.
Study: NCT01018173
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: sc weekly
Study: NCT00009880
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT04135846
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo
Study: NCT02953808
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% weight by volume (w/v) saline solution for intravenous infusion over 1 hour (in Cohort 1) or over 15 hours (in Cohort 2).
Study: NCT02738541
Drug: PLACEBO DENTRIFICE WITHOUT PROPHOSPHATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: PLACEBO DENTRIFICE WITHOUT PYROPHOSPHATE WAS ADVISED TWICE DAILY FOR 6 MONTHS
Study: NCT00389376
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00389376
Drug: Silymarin
Normalized name: silymarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 140 mg every 8 hours
Study: NCT00389376
Drug: Silymarin
Normalized name: silymarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 280 mg single dose
Study: NCT00389376
Drug: Silymarin
Normalized name: silymarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 280 mg single dose + every 8 hours
Study: NCT00389376
Drug: Silymarin
Normalized name: silymarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 560 mg single dose + every 8 hours
Study: NCT00790439
Drug: Heparin
Normalized name: Heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Anticoagulant
Study: NCT02668588
Drug: extended release of placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 intramuscular injection of extended release of placebo
Study: NCT00389376
Drug: Silymarin
Normalized name: silymarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 280 mg every 8 hours
Study: NCT00389376
Drug: Silymarin
Normalized name: silymarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 700 mg single dose + every 8 hours
Study: NCT06094244
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Doses of rosuvastatin of up to 10 mg/d.
Study: NCT01141998
Drug: Calcium, Dietary
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg calcium two times daily. From week 0 to 10 and week 14 to 52.
Study: NCT01059864
Drug: CP-690,550
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 week open-label CP-690,550 10 mg oral tablets administered twice daily starting at Day 0 through Week 12
Study: NCT03815448
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants randomized to methotrexate group will receive active drug, methotrexate. Starting from 5 mg/week, the dosage will be adjusted to 10 mg/week if the participants can tolerate for 2 weeks. After 2 weeks, the dosage will be adjusted to 15 mg/week until the end of the study if the participants can tolerate.
Study: NCT02953808
Drug: GSK2315698
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg/mL stock solution for intravenous infusion over 1 hour (in Cohort 1) or over 15 hours (in Cohort 2). The stock solution will be diluted to obtain dosage levels of 10 mg/hr, 20 mg/hr, or 40 mg/hr.
Study: NCT02846207
Drug: Yiqi huoxue
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buyang Huanwu demolition, which includes: Astragalus 60g, Radix Paeoniae Rubra 15g, ligusticum wallichii 12g, angelica sinensis 20g, earthworm 12g, flos carthami 12g and peach seed 12g. Oral administration, twice one day, for 12weeks.
Study: NCT02846207
Drug: Yiqi group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Astragalus 60g.Oral administration, twice one day, for 12weeks.
Study: NCT00479128
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Starting dose: 12.5 mg/m\^2 IV Over 15-30 minutes
Study: NCT01120470
Drug: OGX-427
Approvals — FDA: no, EMA: no, PMDA: no
Description: OGX-427: Starting within 5 days of randomization, three loading doses at 600 mg IV within the first 10 days of initiating treatment, followed by weekly doses of 1000 mg IV
Study: NCT02617407
Drug: Livionex® Dental Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral application Dental Plaque, Gingivitis and Oral Microbiome Control.
Study: NCT02617407
Drug: PreviDent 5000 plus/Tom's of Maine Children's toothpaste
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral application for Dental Plaque, Gingivitis and Oral Microbiome Control.
Study: NCT02836470
Drug: LB1148
Approvals — FDA: no, EMA: no, PMDA: no
Description: A total of 700 mL of drug product will be administered orally as a split dose before surgery.
Study: NCT02836470
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A total of 700 mL of placebo will be administered orally as a split dose before surgery.
Study: NCT02846207
Drug: Huoxue group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radix Paeoniae Rubra 15g, ligusticum wallichii 12g, angelica sinensis 20g, earthworm 12g, flos carthami 12g and peach seed 12g. Oral administration, twice one day, for 12weeks.
Study: NCT02846207
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextrin,oral administration, twice one day, for 12weeks.
Study: NCT01373008
Drug: Inhaled extra-fine hydrofluoalkane-beclomethasone (QVAR)
Normalized name: beclomethasone Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infants will be randomized for Inhaled QVAR 100 microgram or placebo twice daily with spontaneous tidal breathing for 30 seconds via aerochamber with face mask for the study period.
Study: NCT01541735
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 40 mg dose.
Study: NCT00934739
Drug: Cyclophosphamide, Dexamethasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediately after operation starts cyclophosphamide (50) 1# per day and dexamethasone (0.5) 2# qd for three weeks, in addition to standard postoperative concurrent chemoradiotherapy
Study: NCT00069875
Drug: LY293111
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01445535
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide will be given with siplizumab and etoposide, prednisone, vincristine, doxorubicin and rituximab every 21 days
Study: NCT01445535
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxorubicin will be given with siplizumab and etoposide, prednisone, cyclophosphamide and rituximab every 21 days
Study: NCT02383888
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03367962
Drug: [18F]F-Ara-G
Approvals — FDA: no, EMA: no, PMDA: no
Description: the \[18F\]F-AraG tracer will be administered as a single bolus injection of approximately 5 mCi into a hand or arm vein.
Study: NCT02494973
Drug: mFOLFOX6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acide folinique 400 mg/m² in 2 hours IV (concomitantly to oxaliplatin) D1, followed by 5FU bolus 400 mg/m² in 5-10 minutes IV D1 followed by 5FU 2400 mg/m² IV in 46 hours.